Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant tumor syndrome that affects B1 in 6000 individuals. It is characterized by the development of tumors, named hamartomas, in the kidneys, heart, skin and brain. The latter often cause seizures, mental retardation and a variety of developmental disorders, including autism (Kwiatkowski, 2003) . The tumor suppressor gene TSC1 on chromosome 9q34 encodes hamartin (The TSC1 Consortium, 1997) and TSC2 on chromosome 16p13.3 encodes tuberin (The European Chromosome 16 Tuberous Sclerosis Consortium, 1993) . TSC patients carry a mutant TSC1 or TSC2 gene in each of their somatic cells and loss of heterozygosity has been documented in a wide variety of TSC tumors. Inactivation of TSC1 and TSC2 causes a similar phenotype and tuberin and hamartin form a heterodimer, suggesting that they might affect the same processes. Hamartin can bind tuberin and, thereby, prevent tuberin ubiquitination and degradation. Tuberin is assumed to be the functional component of the complex (Kwiatkowski, 2003; Li et al., 2003; Pan et al., 2004; Astrinidis and Henske, 2005) and has been implicated in the regulation of different cellular functions, such as endocytosis (Xiao et al., 1997) or transcription (Henry et al., 1998) . Tuberin also regulates cell cycle progression by binding to the cyclin-dependent kinase inhibitor p27 and, thereby, preventing p27 degradation via its SCFtype E3 ubiquitin ligase complex (Soucek et al., 1997 (Soucek et al., , 1998 Rosner and Hengstschla¨ger, 2004) . Recent studies in Drosophila and mammalian cells demonstrated that the TSC1/TSC2 complex functions as GTPase-activating protein against Rheb (Ras homolog enriched in brain), which in turn regulates mTOR (mammalian target of rapamycin) signaling. The TSC1/TSC2 complex antagonizes the mTOR signaling network -which has a central role in the regulation of cell growth in response to growth factors, cellular energy and nutrient levels. Upon insulin or growth factor stimulation, tuberin is phosphorylated by several kinases, including AKT, which suppresses its activity (Li et al., 2003; Pan et al., 2004; Astrinidis and Henske, 2005) . mTOR phosphorylates p70S6K (p70 ribosomal protein S6 kinase) on Thr389, which correlates with the activation of p70S6K (Dufner and Thomas, 1999) . Overexpression of TSC2 suppresses phosphorylation of p70S6K on residue Thr389 and p70S6K activation (Dan et al., 2002; Goncharova et al., 2002; Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002; Tee et al., 2002) .
At the physiological level, mutations in tumor suppressor genes drive tumor development by affecting tumor cell number through stimulation of cell proliferation or the inhibition of cell death (Vogelstein and Kinzler, 2004) . The TSC genes have been implicated in the regulation of cell cycle (Soucek et al., 1997 (Soucek et al., , 1998 Rosner and Hengstschla¨ger, 2004) and here, we investigated whether these genes are also involved in the regulation of cell death. The BCL-2 family of proteins constitutes a critical intracellular checkpoint in the intrinsic pathway of apoptosis. The founding member BCL-2 and its close homolog BCL-X L inhibit apoptosis, whereas other members of the BCL-2 family, such as BAD or BAX, are proapoptotic (Danial and Korsmeyer, 2004) . Several kinases have been noted to phosphorylate BAD. For example, the p90S6K (p90 ribosomal protein S6 kinase) phosphorylates BAD on Ser112 and the p70S6K and AKT phosphorylate BAD on Ser136. Phosphorylated BAD is sequestered into the cytosol freeing BCL-2 and/or BCL-X L to promote survival. Only the active, nonphosphorylated BAD heterodimerizes with BCL-2 or BCL-X L at mitochondrial membrane sites causing sensitivity to apoptotic triggers. Changes in BAD phosphorylation occur rapidly in response to apoptotic or survival stimuli (Zha et al., 1996; Datta et al., 1997; del Pesco et al., 1997; Blume-Jensen et al., 1998; Bonni et al., 1999; Shimamura et al., 2000; Harada et al., 2001) .
Here, we report that tuberin triggers apoptosis. Tuberin affects the phosphorylation status of p70S6K (Thr389) and of BAD (Ser136) and the interaction of BAD/BCL-2 and BAD/BCL-X L . Tuberin's potential to induce apoptosis is negatively regulated by AKT phosphorylation, depends on BAD and is significantly reduced by a disease-causing mutation within TSC2. The latter emphasizes the relevance of the tuberinmediated regulation of apoptosis for the development of the disease TSC.
Results
Ectopic expression of TSC proteins induces cell shrinkage, chromatin condensation and DNA degradation To test the effects of modulated TSC gene expression on the regulation of cell death, we generated HeLa cell pools selected for overexpression of ectopic tuberin or hamartin ( Figure 1a ). Common features of cells undergoing apoptosis are cell shrinkage, DNA fragmentation or nuclear chromatin condensation (Danial and Korsmeyer, 2004) . After transferring these cells into 0.1% fetal calf serum (FCS) for 48 h, cell size was determined by cytofluorometric forward scatter (FSC) analyses. The TSC genes triggered cell shrinkage detected by the appearance of cells of smaller size (Figure 1b) . To confirm the induction of apoptosis under these conditions, DNA fragmentation was investigated by the detection of cells with sub-G1 DNA content. A significant increase of sub-G1 cells was detected upon TSC gene overexpression (Figure 1c ). Under the same experimental conditions, these cells were stained with Hoechst 33258/propidium iodide (HOPI) to monitor nuclear chromatin condensation and cell death. Viable and apoptotic cells were discerned and counted under the microscope. Quantitative analyses of the percentage of dead cells revealed that TSC1 and TSC2 significantly induced apoptosis in 0.1% FCS (Figure 1d ). Collectively, these data demonstrate that the TSC genes induce apoptosis.
Tuberin affects BAD activity Overexpression of TSC1/2 is known to suppress phosphorylation of p70S6K on residue Thr389 and p70S6K activation (see Introduction). To confirm this capacity in the cell system used here, we transiently overexpressed TSC1 or TSC2 in HeLa cells. Western blot analyses revealed that the level of p70S6K phosphorylation on residue Thr389 was downregulated upon TSC gene overexpression ( Figure 2a ). As p70S6K is known to phosphorylate BAD at Ser136 (Harada et al., 2001) , we next tested whether the downregulation of p70S6K activity upon TSC gene overexpression is accompanied by effects on the BAD Ser136 phosphorylation status. HeLa cells were transiently co-transfected with TSC1 or TSC2 and BAD to allow for a better visualization of the BAD phosphorylation status. In mouse cells, a 23-kDa BAD short protein (BAD S ) and a 28-kDa BAD long protein (BAD L ) can be detected. Most murine tissues express BAD S , whereas BAD L levels are more variable. In human cells, only the BAD S protein is detectable (Ranger et al., 2003) . The ectopically overexpressed BAD is the long protein BAD L , which cannot be detected in HeLa cells (Figure 2b ). Western blot analyses showed that ectopic TSC proteins trigger a downregulation of BAD phosphorylation on residue Ser136 after 24 h in 0.1% FCS. Phosphorylation of BAD at Ser112, which is mediated by p90S6K (Bonni et al., 1999; Shimamura et al., 2000) , was not affected by the TSC proteins (Figure 2b ). Nonphosphorylated BAD binds and inhibits BCL-2 and BCL-X L and promotes apoptosis (see Introduction). Accordingly, we wanted to test the effects of ectopic tuberin on BAD/BCL-2 and BAD/BCL-X L complex formation. HeLa cells were transiently transfected with BAD þ BCL-2 or with BAD þ BCL-2 þ TSC2 as described above. Immunoprecipitations with anti-BAD antibody were performed after 24 h in 0.1% FCS. Immunoblot analyses revealed that TSC2 triggers an upregulation of the interaction of BAD and BCL-2 (Figure 2c) . Furthermore, such experiments revealed that TSC2 also triggers an upregulation of the interaction of BAD and BCL-X L (Figure 2d ).
To investigate whether apoptosis is induced in these cells under these experimental conditions, we analysed the cleavage of poly(ADP-ribose)polymerase (PARP), another hallmark of apoptosis (Danial and Korsmeyer, 2004) . Western blot analysis revealed an upregulation of the amount of cleaved PARP upon TSC2 overexpression under the same experimental conditions as described above (Figure 2e ). To further confirm that transient TSC gene expression induces cell death of HeLa cells in 0.1% FCS, we performed luciferase assays. After co-transfection with a luciferase reporter plasmid, only viable cells harbor the potential to express luciferase activity. The luciferase activity measured in cell lysates represents the amount of viable cells in the population. Luciferase activities are indirect indicators for apoptosis. In cell populations with more luciferase activity in the lysates, more cells are viable and less apoptosis is present. In the past, this approach has been used to analyse the apoptotic effects of a variety of different genes (see e.g. Wohlfart et al., 2004) . Besides other detections of apoptosis, we have also chosen this type of experiments, because the report showing that p70S6K regulates apoptosis via BAD Ser136 phosphorylation also made use of this approach (Harada et al., 2001) . Our experiments demonstrated that transient overexpression of BAD, TSC1 or TSC2 induced cell death (Figure 3a-d) . These data were also confirmed by studying apoptosis via detection of DNA fragmentation. Analysis of the amount of sub-G1 cells within the green fluorescent protein (GFP)-positive cell pools also demonstrated that transient overexpression of BAD, TSC1 or TSC2 induced apoptosis (Figure 3e ). Western blot analyses further revealed that ectopic BAD triggered apoptosis without any effects on the protein levels of tuberin, hamartin or p70S6K and without effects on the phosphorylation status of p70S6K Thr389 Tuberin activates the proapoptotic molecule BAD A Freilinger et al ( Figure 3a ). These data provide evidence that BAD acts only downstream of these molecules in inducing apoptosis.
AKT negatively regulates tuberin's potential to trigger apoptosis Next, we wanted to assess whether restoration of high intracellular p70S6K activity is capable of suppressing TSC gene-mediated apoptosis. To answer this question, we chose experimental conditions of transient expression of high ectopic p70S6K levels. HeLa cells were transiently transfected with TSC1, TSC2, TSC1 þ p70S6K, TSC2 þ p70S6K or p70S6K. Western blot analysis revealed that even in TSC gene overexpressors, the high levels of ectopic p70S6K lead to high intracellular levels of p70S6K activity, detected by the amount of p70S6K phosphorylated on residue Thr389. The ectopic p70S6K activity levels were too high to be significantly blocked by ectopic tuberin or hamartin ( Figure 3b ). Accordingly, BAD Ser136 phosphorylation increased upon p70S6K expression even in TSC2-overexpressing cells (Figure 3c ). In these experiments, ectopic p70S6K activity had no effects on TSC protein levels, neither on the endogenous nor on the ectopic (Figure 3b ). Luciferase assays and sub-G1 cell analyses demonstrated that restoration of high intracellular p70S6K activity interfered with TSC After 24 h in 0.1% FCS, immunoprecipitations were performed using an anti-BAD antibody. After SDS-PAGE, the precipitates were immunoblotted with anti-BCL-2 antibody and with anti-BAD antibody. Immunprecipitations without antibody were co-analysed as negative control. Tuberin, BCL-2 and BAD L expression was also determined by Western blot analyses. (d) HeLa cells were transfected with BAD or with BAD þ TSC2. After 24 h in 0.1% FCS, immunoprecipitations were performed using an anti-BAD antibody. After SDS-PAGE, the precipitates were immunoblotted with anti-BCL-X L antibody and with anti-BAD antibody. Immunprecipitations without antibody were co-analysed as negative control. The asterisk indicates an unspecific band. Tuberin and BAD L expression was also determined by Western blot analyses. (e) Under the experimental conditions described above, PARP cleavage was investigated by immunoblot analysis to prove TSC2-mediated apoptosis (for the proof of TSC2-mediated apoptosis under these experimental conditions, see also the data presented in Figure 3 ). BCL-2 transfected cells were co-analysed as control. The bands were densidometrically analysed. Signals for cleaved PARP were normalized to a-tubulin. The result of the control transfection experiment was set to 1.
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A Freilinger et al protein-induced apoptosis (Figure 3d and e). AKT phosphorylation of tuberin at Ser939 or Thr1462 decreases its ability to inhibit p70S6K activity (Dan et al., 2002; Goncharova et al., 2002; Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002; Tee et al., 2002) . The TSC2 SATA mutant (S939A/T1462A), which we once again proved not to be phosphorylated on Thr1462 (Figure 4a ) and to harbor a higher potential to downregulate p70S6K activity (Figure 4b ), induced apoptosis with significantly higher efficiency than wildtype TSC2 (Po0.05; Student's t-test; Figure 4c ). These data support the notion that the potential to regulate p70S6K is associated with tuberin's effects on apoptosis. In addition, these findings provide evidence that AKT phosphorylation of tuberin at Ser939 or Thr1462 negatively affects tuberin's ability to trigger apoptosis.
This notion is further supported by our finding that cooverexpression of active AKT has statistically significant negative effects on tuberin-mediated apoptosis (Po0.05; Student's t-test; Figure 4d and e).
BAD is a mediator of tuberin's effects on apoptosis
To confirm that BAD is a mediator of the effects of tuberin on apoptosis, we generated BADÀ/À cells via SV40 transformation of cells from the BADÀ/À animal model. We compared BADÀ/À cells transfected with the empty vector control with BADÀ/À cells, in which BAD protein expression has been reintroduced via transient transfection (Figure 5a ). To analyse the relevance of BAD for tuberin's effects on apoptosis, we performed luciferase assays and sub-G1 cell analyses Immunoblot analyses of tuberin, hamartin, total p70S6K, phosphorylated (Thr389) p70S6K and a-tubulin were performed. (c) HeLa cells transiently transfected with TSC2 or with TSC2 þ p70S6K were co-transfected with BAD to allow better visualization of BAD Ser136 phosphorylation via immunoblotting. The bands of two independent experiments were densidometrically analysed. Signals for ectopic Ser136 phosphorylated BAD were normalized to BAD. The result of the TSC2 transfection experiment was set to 1. TSC2 þ p70S6K data represent means7SDs. (d) HeLa cells were transfected with control vector, BAD, TSC1, TSC2, TSC1 þ p70S6K, TSC2 þ p70S6K and p70S6K. Cells were co-transfected with a luciferase reporter plasmid. After 24 h in 0.1% FCS, the viability of the cells was analysed by luciferase activity. Cell death significantly increased upon overexpression of TSC1 or TSC2 compared with control cells (mean set as 100%). High ectopic p70S6K activity suppressed this effect (Po0.05; Student's t-test). (e) HeLa cells were transfected with control vector, BAD, TSC1, TSC2, TSC1 þ p70S6K, TSC2 þ p70S6K and p70S6K. Cells were co-transfected with a GFP expression plasmid. After growth in 0.1% FCS, apoptosis was cytofluorometrically analysed by determination of sub-G1 cells (DNA degradation) within the GFP-positive cell pools. The amount of sub-G1 cells significantly increased upon overexpression of TSC1 or TSC2 compared with control cells. High ectopic p70S6K activity suppressed this effect (Po0.05; Student's t-test).
after transient transfection of BADÀ/À cells with TSC2, TSC2 þ BAD and BAD alone. Importantly, these experiments demonstrated that co-overexpression of BAD together with TSC2 significantly increased apoptosis compared with cells overexpressing TSC2 only, as well as with cells overexpressing BAD only (Figure 5c and d). These data allow the conclusion that the efficiency of tuberin to induce cell death is higher in a BAD-positive background. This notion is further supported by our finding that ectopic TSC2 mediates stronger apoptotic effects in BAD þ / þ cells than in the BADÀ/À counterparts (Figure 5b and c) . In addition, the finding that BAD alone triggers apoptosis less efficiently than BAD þ TSC2 in BADÀ/À cells suggests that a specific amount of ectopic BAD might be inactivated owing to phosphorylation on residue Ser136 via endogenous p70S6K. Simultaneous downregulation of this p70S6K activity via ectopic tuberin increases BAD's potential to trigger apoptosis. TSC2 overexpression mediated a weak apoptotic effect in BADÀ/À cells. Although this effect was weak, 26.33% sub-G1 cells in TSC2-overexpressing cells compared to 22.42% sub-G1 cells in control vector-transfected BADÀ/À cells, these data suggest that, besides regulating BAD, tuberin can also use BAD-independent mechanisms to induce apoptosis. Still, taken together, these data demonstrate BAD to be a major mediator of tuberin-induced apoptosis.
Tuberin-mediated apoptosis interferes with IGF-1 and is diminished in cells with already downregulated mTOR activity Ectopic overexpression of BAD triggers apoptosis. IGF-1 negatively affects BAD-mediated apoptosis by inducing p70S6K phosphorylation of BAD Ser136 (Harada et al., 2001) . Here, we found tuberin to downregulate p70S6K activity and the phosphorylation of BAD Ser136. These data suggest that the survival factor IGF-1 and the apoptotic function of tuberin counteract. Indeed, we found that IGF-1 upregulates BAD Ser136 phosphorylation and negatively affects BAD-mediated apoptosis and that high ectopic levels of tuberin interfere with these IGF-1-mediated cell survival effects (Po0.05; Student's t-test; Figure 6a and b). Rapamycin is a potent inhibitor of mTOR and has been shown to induce apoptosis by regulating p70S6K-mediated phosphorylation of BAD Ser136 (Harada et al., 2001) . As our findings provide evidence that tuberin is inducing apoptosis affecting the same 
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A Freilinger et al mechanism, the apoptotic effects of ectopic TSC2 should be diminished in cells, in which mTOR is already downregulated. Luciferase assays in cells with and without rapamcyin treatment revealed that both TSC2 and rapamcyin can induce apoptosis in low serum under the experimental conditions used here and that TSC2 cannot induce apoptosis in already apoptotic rapamycin-treated cells with the same efficiency as in untreated cells (Figure 6c ). These data provide additional support for our model that TSC2 regulates apoptosis by inhibiting mTOR activity.
Loss of tuberin mediates resistance to apoptosis
Next, we made use of the tuberin-positive EEF4 cells and their tuberin-negative counterparts, EEF8 cells. We found EEF8 cells to express higher levels of BAD protein. We also detected a higher amount of phosphorylated BAD on Ser136 in cells without functional tuberin. Only a very small increase of Bad phosphorylation in tuberin-negative cells was detected (Figure 7a ). Low serum treatment strongly induced apoptosis in EEF4 cells, whereas their tuberin-negative counterparts, EEF8 cells, exhibited a significantly diminished apoptotic response under the same experimental conditions (Po0.05; Student's t-test; Figure 7b ). Re-introduction of functional tuberin in EEF8 cells re-established a high susceptibility to apoptosis via treatment with low serum (Figure 7c and d) . Using these cells, we further detected that loss of TSC2 also mediates significant resistance to apoptosis induced by staurosporine, another wellknown apoptosis inducer (see e.g. Arrebola et al., 2005) (Po0.05; Student's t-test; Figure 7e ). Our findings that tuberin increases susceptibility to apoptosis (see above) together with these observations that loss of functional TSC2 mediates resistance to different apoptotic stimuli strongly suggest that cells without functional tuberin, such as cells that develop to hamartomas in TSC patients, are better protected against apoptotic stimuli.
A pathogenic mutation within TSC2 reduces tuberin's potential to regulate apoptosis Given tuberin's role in apoptosis regulation contributes to the development of the disease TSC, natural occurring disease-causing mutations within TSC2 would be expected to negatively affect tuberin's potential to trigger apoptosis. Mutation analysis of the GAP-related domain of TSC2 in TSC patients led to the characterization of disease-associated mutations including missense mutations that were shown to occur as de novo mutations in sporadic TSC cases. One of such reported mutations has been introduced into the TSC2 mutant 6 2/25 (C to G at nucleotide 4947 ¼ Asn to Lys at amino acid 1643) (Maheshwar et al., 1997) . Luciferase assays after transient transfections and 24 h in 0.1% FCS demonstrated that introduction of this disease-causing mutation into TSC2 significantly reduced tuberin's potential to trigger apoptosis (Po0.05; Student's t-test; Figure 8a and b). These data emphasize the relevance of the function of tuberin in the regulation of apoptosis for the development of the disease.
TSC1's apoptotic effects depend on TSC2
We also found that ectopic expression of TSC1 triggers apoptosis (Figures 1-3 ). Tuberin and hamartin form a complex of which tuberin is assumed to be the functional component (see Introduction). Hamartin is suggested to mediate different effects only by regulating/ activating tuberin. Accordingly, it was of interest to test whether overexpression of TSC1 can also induce apoptosis in a TSC2-negative background. Luciferase 
Discussion
Uncontrolled cell cycle progression and cell growth are key properties of tumor cells. However, it seems that the Tuberin activates the proapoptotic molecule BAD A Freilinger et al life of most cells that acquire potentially neoplastic characteristics is rapidly terminated via apoptosis. Survival and further progression of only rare neoplastic cells is allowed by defects in the regulation of apoptosis. Oncogenes and tumor suppressor genes have been shown to be involved in the regulation of these processes (Vogelstein and Kinzler, 2004 ). The TSC tumor suppressor genes have been shown to be potent negative regulators of cell cycle and cell size control (see Introduction) . Here, we demonstrate that high levels of tuberin trigger apoptosis accompanied by p70S6K inactivation, downregulation of BAD phosphorylation on residue Ser136 and upregulation of the interaction between BAD and BCL-2 or BCL-X L (Figure 9 ). We provide evidence that BAD is a strong mediator of tuberin's effects on apoptosis regulation, but also that tuberin can trigger apoptosis in a BAD-independent manner. The activities of IGF, AKT and p70S6K promote cell survival. This pathway has been implicated as an antiapoptotic regulator in many different cell death paradigms, including withdrawal of extracellular signaling factors, oxidative and osmotic stress, irradiation and treatment of cells with chemotherapeutic drugs and ischemic shock (Franke et al., 2003) . Insulin and IGFs phosphorylate and activate their cognate tyrosine kinase receptors (INRs), triggering the recruitment and phosphorylation of insulin receptor substrates (IRSs), to generate a docking site at the membrane for the phosphatidylinositide-3 0 -OH kinase (PI3K). Phosphorylation of the membrane lipid phosphatidylinositol 4,5-biphosphate (PIP 2 ) by PI3K produces the second messenger phosphatidylinositol 3,4,5-triphosphate (PIP 3 ), which activates AKT (Li et al., 2003; Pan et al., 2004; Figure 9) . AKT is assumed to stimulate mTOR signaling by inhibiting the function of the TSC proteins (Dan et al., 2002 : Inoki et al., 2002 Manning et al., 2002) . Here, we report tuberin to interfere with IGF-1-induced BAD Ser136 phosphorylation and cell survival. We found that co-overexpression of active AKT has a negative effect on the level of apoptosis induced by ectopic TSC2. The TSC2 SATA mutant (S939A/T1462A), which cannot be phosphorylated by AKT and mediates increased negative effects on p70S6K
Figure 8 TSC2's apoptotic potential is negatively affected by a pathogenic mutation, and TSC1's effects depend on TSC2. (a) Mammalian expression vectors, empty as a negative control or harboring either full-length human TSC2 cDNA or the naturally occurring disease-causing TSC2 mutant 6 2/25 (C to G at nucleotide 4947 ¼ Asn to Lys at amino acid 1643), were transiently transfected into HeLa cells. Ectopic tuberin expression was confirmed by Western blot analysis. (b) Cells, transfected as described above, were co-transfected with a luciferase reporter plasmid. After 24 h in 0.1% FCS the viability of the cells was analysed by luciferase activity. The naturally occurring disease-causing mutation significantly reduced tuberin's potential to induce cell death (Po0.05; Student's t-test). The mean of the empty vector control experiments has been set as 100%. EEF4 (TSC2-positive) cells (c) and EEF8 (TSC2-negative) cells (d) were transfected with empty vector control or TSC1 and ectopic hamartin expression was confirmed by Western blot analyses. (e) Luciferase assays for monitoring apoptosis were performed upon co-transfection with a luciferase reporter plasmid. In 0.1% FCS, TSC1 could not trigger apoptosis in TSC2-negative cells (the means of the control experiments were set to 100%).
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A Freilinger et al activity , significantly increases tuberin's proapoptotic effects. High ectopic levels of p70S6K interfere with tuberin's proapoptotic effects and TSC2 cannot induce apoptosis in already apoptotic rapamycin-treated cells with the same efficiency as in untreated cells. Taken together, these data provide evidence that tuberin's potential to regulate mTOR and p70S6K is associated with its influence on apoptosis. We cannot exclude that AKT affects this regulation by both, phosphorylation of tuberin and phosphorylation of BAD. BAD's residue Ser136 is phosphorylated by p70S6K (Harada et al., 2001) and by AKT (Datta et al., 1997; del Pesco et al., 1997; Blume-Jensen et al., 1998) . This is of particular interest as it was reported that PI3K and AKT activation by IGF depends on TSC proteins. A negative feedback loop is responsible for the regulation of AKT signaling via mTOR/S6K: IRS 1/2 stability and activity is compromised in tuberin-negative cells caused by their phosphorylation via p70S6K (Astrinidis and Henske, 2005; Harrington et al., 2005) . Accordingly, tuberin's negative effects on p70S6K activity could downregulate p70S6K-and activate AKT-mediated BAD S136 phosphorylation. Tuberin has also been shown to be regulated by cellular energy levels and to play an essential role in the cellular energy response pathway. Under energy starvation conditions, the AMP-activated protein kinase (AMPK) phophorylates tuberin on residues Thr1227 and Ser1345. This phosphorylation by AMPK activates tuberin and is required for the regulation of cell size control in response to energy deprivation. Furthermore, this phosphoryation by AMPK protects cells from energy deprivation-induced apoptosis .
Taken together, these and our findings suggest that depending on the exogenous triggers of apoptosis, tuberin might fulfill different functions. This notion is further supported by the recent finding that the Rheb/mTOR/p70S6K pathway also induces depletion of IRS1 and IRS2. Constitutive activation of this cassette, whether by genetic deletion of TSC1 or TSC2 or by ectopic expression of Rheb, is sufficient to induce insulin resistance. These data suggest that inappropriate activation of the Rheb/mTOR/p70S6K cassette imposes a negative feedback program to attenuate IRS-dependent processes such as cell survival (Shah et al., 2004) .
Our data that tuberin increases susceptibility to apoptosis suggest that cells lacking functional tuberin owing to disease-causing mutations, such as the cells that give rise to the lesions of TSC patients, are better protected against apoptotic stimuli. Such a scenario may underlie the development of inappropriate growths (hamartomas), which is the hallmark of TSC (Kwiatkowski, 2003) . Indeed, we found low serum treatment and staurosporine to mediate stronger apoptotic effects in tuberin-positive cells compared to their tuberinnegative counterparts. This finding is in agreement with the very recently reported data that ectopic TSC2 expression increases the susceptibility of the TSC2-null renal tumor cell line ERC-18 to apoptosis induced by okadaic acid and the PI3K inhibitor, LY294002 (Kolb et al., 2005) . We also found that ectopic hamartin can trigger apoptosis. Importantly, in tuberin-negative cells, hamartin cannot regulate apoptosis. Hamartin stabilizes tuberin by inhibiting its interaction with the HERC1 ubiquitin ligase (Chong-Kopera et al., 2006) . Accordingly, it is possible that a small increase (under the detection level of Western blot analyses) of tuberin protein levels upon overexpression of hamartin is enough to mediate hamartin's effects. However, we favor another model: tuberin alone is active to induce apoptosis (that is why increased levels of tuberin alone trigger apoptosis), but hamartin can hyperactivate tuberin (that is why we found S6K regulation and apoptosis upon hamartin overexpression). Finally, we report that a naturally occurring disease-causing mutation within TSC2 significantly reduces tuberin's potential to regulate apoptosis. This finding underscores the relevance of the study reported here for the human pathophysiology of TSC. 
Materials and methods
Cells, tissue culture, flow cytometry and apoptosis detection HeLa (human cervical carcinoma) cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Tuberin-negative EEF8 and tuberin-positive EEF4 cells are rat fibroblasts derived from the Eker rat embryos homozygous for the Eker mutant and wild-type TSC2 gene, respectively (compare e.g. Soucek et al., 1998) . BAD þ / þ and BADÀ/À mouse embryonic fibroblasts (MEFs) were immortalized by transfection with a plasmid containing SV40 genomic DNA. Primary MEFs were plated in six-well plates (2 Â 10 5 cells per well) and were transfected with 1 mg of SV40 genome total DNA using Fugene (Roche, Mannheim, Germany) according to the manufacturer's instructions. Stable immortalized clones were generated through serial dilution. All cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% calf serum and antibiotics (30 mg/l penicillin and 50 mg/l streptomycin sulfate). All cultures were kept at 371C and 5% CO 2 and routinely screened for mycoplasma. To study IGF-1 effects, 100 ng/ml IGF-1 (Sigma, Vienna, Austria) was added to the medium 30 min before analysis. To induce apoptosis, 25 nM staurosporine (Sigma), and to inhibit intracellular mTOR activity, 50 nM rapamycin (Sigma) were added to the medium. For cytofluorometric analyses of FSC (cell size -cell shrinkage) and DNA distribution (sub-G1 cells -DNA degradation), cells were harvested by trypsinization and fixed by rapid submersion in ice-cold 85% ethanol. After overnight fixation at À201C, cells were pelleted and DNA was stained in 1 ml of staining solution (0.25 mg/ml propidium iodide, 0.05 mg/ml RNase, 0.1% Triton X-100 in citrate buffer, pH 7.8). Cells were analysed on a Beckton Dickinson FACScan (Beckton Dickinson, San Jose, CA, USA). For the analyses of the amount of sub-G1 cells (DNA degradation) after transient transfection, GFP-positive cells were selectively gated and DNA distribution was analysed (Rosner et al., 2003) . To monitor nuclear chromatin condensation and cell death, Hoechst 33258 (Sigma) and propidium iodide (Sigma) were added directly to the culture medium to final concentrations of 5 and 2 mg/ml, respectively. After an incubation period of 1 h at 371C, the cells were transferred onto glass slides and microscopically analysed with a DAPI filter. Viable and apoptotic cells were discerned and counted (Grusch et al., 2002) .
Transfections
For transfections, the following plasmids were used: the empty pcDNA3 vector; pcDNA3 harboring full-length human wildtype TSC1 or TSC2 (already used in Miloloza et al., 2000; Rosner and Hengstschla¨ger, 2004) ; pcDNA3 harboring fulllength BCL-2 (Borner, 1996) ; pcDNA3 harboring full-length BAD (Harada et al., 2001) ; the pSG5 vector, empty as a negative control or harboring either full-length human TSC2 cDNA or the TSC2 naturally occurring disease-causing mutant 6 2/25 (C to G at nucleotide 4947 ¼ Asn to Lys at amino acid 1643) (already used in Rosner et al., 2003) ; the pRK7 vector, empty or harboring full-length p70S6K ; pcDNA3 harboring the TSC2 SATA mutant (S939A/T1462A) ; the Myc-tagged activated AKT (Upstate, Lake Placid, NY, USA); the GFP-spectrin expression vector described in Kalejta et al. (1997) . All cell transfections were performed using the Lipofectamine reagents obtained from Invitrogen (Life Technologies, Lofer, Austria) following the transfection protocol provided by the manufacturer.
Luciferase assays Cells were transfected as described above and co-transfected with a luciferase reporter plasmid. Cell pellets were lysed in reporter lysis buffer (Promega, Mannheim, Germany), and to achieve complete cell lysis, the cell suspensions were immediately frozen at À801C and then thawed rapidly. Subsequently, the lysates were centrifuged at 12 000 g for 1 min at room temperature and the supernatant was assayed for luciferase activity. Twenty microliters of supernatant was mixed with 100 ml luciferase assay reagent (Promega), and luminescence was measured with a luminometer (FLUOstar, BMG Labtechnologies, Germany). The luciferase activity was recorded as relative light units. The reduction of luciferase activity is a consequence of cell death (Harada et al., 2001) .
Immunoblotting Protein extracts were prepared in buffer containing 20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethane sulfonic acid, pH 7.9, 0.4 M NaCl, 2.5% glycerol, 1 mM ethylenediamine tetraacetate, 1 mM phenylmethylsulfonylfluoride, 0.5 mM NaF, 0.5 mM Na 3 VO 4 , 2mg/ml leupeptin, 2 mg/ml aprotinin, 0.3 mg/ml benzamidinchloride, 10 mg/ml trypsin inhibitor and 0.5 mM dithiothreitol. Cells were lysed by freezing and thawing. After 20 min on ice, the extracts were centrifuged and the supernatants were stored at À701C. Protein concentrations were determined using the Bio-Rad (Hercules, CA, USA) protein assay reagent with bovine serum albumin as the standard. Proteins were run on an sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose. Blots were stained with Ponceau-S to visualize the loaded protein. 
Immunoprecipitations
For immunoprecipitations, proteins were prepared as described above for immunoblotting. Crude cell extracts were precleared with 40 ml Protein G-Sepharose beads for 30-60 min at 41C and incubated with anti-BAD antibody (Cell Signaling). After complex formation, immunoprecipitates were washed twice with buffer containing 1% NP-40, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 10 mM b-Glycerophosphate, 1 mM NaF, 0.1 mM Na 3 VO 4 , 0.2 mM polymethyl sulfonyl fluoride, 2 mg/ml leupeptin, 2 mg/ml aprotinin, 0.3 mg/ml benzamidinchloride and 10 mg/ml trypsin inhibitor. Western blot analysis and the antibodies used for immunoblot detection are described above.
Statistical analysis
The significance of the observed differences was determined by Student's t-test (paired, two-tailed) using GraphPad INSTAT software. P-values >0.05 are defined as not significant.
